ADC Therapeutics S.A. (ADCT) News

ADC Therapeutics S.A. (ADCT): $8.30

0.44 (+5.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADCT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter ADCT News Items

ADCT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ADCT News Highlights

  • For ADCT, its 30 day story count is now at 5.
  • Over the past 22 days, the trend for ADCT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ADCT are ADC, DRUG and SA.

Latest ADCT News From Around the Web

Below are the latest news stories about ADC Therapeutics SA that investors may wish to consider to help them evaluate ADCT as an investment opportunity.

ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022

LAUSANNE, Switzerland, February 24, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, March 3, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2021 and provide business updat

Yahoo | February 24, 2022

ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report

LAUSANNE, Switzerland, February 17, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today unveiled its first Environmental, Social and Governance (ESG) report detailing the Company’s focus on patient care and sustainable innovation. The report marks a milestone in the Company’s evolution an

Yahoo | February 17, 2022

ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline

LAUSANNE, Switzerland, February 08, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today will provide insight into its ADC platform and solid tumor pipeline during a live webcast from 9:00 to 11:00 a.m. EST.

Yahoo | February 8, 2022

ADC Therapeutics to Participate in Guggenheim Oncology Conference

LAUSANNE, Switzerland, February 02, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the virtual Guggenheim Oncology Conference on Wednesday, February 9th at 9:30 a.m. EST.

Yahoo | February 2, 2022

Is ADC Therapeutics (NYSE:ADCT) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | February 2, 2022

ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

LAUSANNE, Switzerland, January 20, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it will host a webcast highlighting its ADC platform and solid tumor pipeline on Tuesday, February 8, from 9:00 to 11:00 a.m. ET.

Yahoo | January 20, 2022

H.C. Wainwright Thinks ADC Therapeutics’ Stock is Going to Recover

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on ADC Therapeutics (ADCT – Research Report), with a price target of $55.00. The company's shares closed last Tuesday at $16.94, close to its 52-week low of $16.35. According to TipRanks.com, Burns has 0 stars on 0-5 stars ranking scale with an average return of -18.3% and a 19.8% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Turning Point Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for ADC Therapeutics with a $44.50 average price target.

Brian Anderson on TipRanks | January 19, 2022

ADC Therapeutics inks exclusive license with MTPC to develop and commercialize ZYNLONTA

ADC Therapeutics (ADCT) has signed an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation ((MTPC)) for the development and commercialization of ZYNLONTA

Seeking Alpha | January 18, 2022

ADC Therapeutics, Mitsubishi Tanabe Ink Zynlonta Licensing Pact In Japan

ADC Therapeutics SA (NYSE: ADCT) has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation to develop and commercialize Zynlonta (loncastuximab tesirine-lpyl) for all hematologic and solid tumor indications in Japan. Under the agreement terms, ADC Therapeutics will receive an upfront payment of $30 million and up to an additional $205 million in milestones payments. ADC Therapeutics will also receive sales-based royalties ranging in percentage from the high teens to th

Yahoo | January 18, 2022

ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

LAUSANNE, Switzerland, January 18, 2022--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, today announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of ZYNLONTA® (loncastuximab tesirine-lpyl) for all hema

Yahoo | January 18, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4368 seconds.